|Bid||33.64 x 120700|
|Ask||33.60 x 6100|
|Day's Range||32.22 - 34.09|
|52 Week Range||24.25 - 52.82|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||10.00|
|Earnings Date||May 06, 2020|
|Forward Dividend & Yield||0.84 (2.48%)|
|Ex-Dividend Date||May 21, 2020|
|1y Target Est||N/A|
To the annoyance of some shareholders, Fresenius SE KGaA (ETR:FRE) shares are down a considerable 35% in the last...
It's been a good week for Fresenius SE & Co. KGaA (ETR:FRE) shareholders, because the company has just released its...
(Bloomberg Opinion) -- It isn’t just Unilever NV that’s struggling to sell more food. Rival Nestle SA now expects to come up short of its self-imposed sales-growth target this year, and it’s counting on acquisitions to put it back on track.While Chief Executive Officer Mark Schneider met the lower end of a goal for underlying operating margin 12 months early, it will take at least another year for the owner of the Nesquik and Nespresso brands to reach and sustain its annual sales growth objective of 4-6%, partly due to the effect of disposals.It’s a rare misstep for Nestle’s first external CEO for almost 100 years. Even with the 2% drop on Thursday, the shares are up more than 40% since his arrival in January 2017, outpacing Unilever. While Schneider’s made a good start selling off underperformers and making purchases in faster growing areas, such as coffee, pet food and meat substitutes, more reshaping is needed. He has traded — either acquired or moved out of — businesses that accounted for about 12% of total sales in 2017. That’s ahead of his target for changing up 10% by the end of 2020. He’s not done yet. From here the focus will be more on acquisitions than disposals.While expanding in the right growth markets is key, Schneider should also go further in pruning the Swiss food giant. Possible culprits for offloading could be parts of the U.S. frozen foods business, especially pizzas, or some water assets, such as those mainstream brands that can’t be taken up market. The fact that Nestle wrote down the value of its Yinlu business in China could be a prelude to an exit from difficult divisions, for example making peanut milk. However, selling off these businesses may be trickier than previous disposals in confectionery, skincare and ice cream.There’s also a risk that Schneider, in an effort to turbocharge growth, becomes less disciplined when he buys. He indicated that he’s open to a wide array of options, the most promising being small or mid-sized purchases, particularly in the hot market for nutrition and metabolism. He lamented that last year was heavy on disposals, but light on purchases. That should change this year, but he shouldn’t be too eager and so strike rash deals.Schneider is comfortable in the pharmaceutical space, having led German healthcare company Fresenius SE before joining Nestle. Medical nutrition not only has higher growth prospects and margins than many food areas, but it is also less constrained by competition rules because Nestle doesn’t have such a big position. He most recently bolstered Nestle’s medical nutrition arm by acquiring gastrointestinal medication Zenpep and increased the investment in Aimmune Therapeutics Inc., which has developed a product to counter the effects of peanut allergies. It indicates that this area, particularly treatments related to the body’s metabolism, is likely to be a bigger focus.To fund any large-scale ambitions, Schneider has Nestle’s stake in L’Oreal SA, worth about 35 billion euros ($38 billion), to play with. The company has always said that it won’t part with this holding unless it has a strategic use for the proceeds, but but he seemed to be more open to an exit on Thursday. Small- to medium-sized deals wouldn’t require any change. A bigger transaction — which can’t be ruled out — might.Either way, Schneider can’t afford to take the wrong turn. Not only is activist Dan Loeb still on the register, but Nestle’s valuation has increased significantly under his tenure. The shares trade on about 22 times forward earnings, compared with about 20 times for Unilever.The premium is justified by Unilever’s recent sales stumble, as well as its slower pace of portfolio change and less focused approach to acquisitions. That doesn’t mean Nestle won’t be punished if it disappoints in the same way as its rival.To contact the author of this story: Andrea Felsted at firstname.lastname@example.orgTo contact the editor responsible for this story: Melissa Pozsgay at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Let's talk about the popular Fresenius SE & Co. KGaA (ETR:FRE). The company's shares saw a double-digit share price...
While not a mind-blowing move, it is good to see that the Fresenius SE & Co. KGaA (ETR:FRE) share price has gained 20...
Stephan Sturm has been the CEO of Fresenius SE & Co. KGaA (ETR:FRE) since 2016. First, this article will compare CEO...
The group said both Fresenius Medical Care , the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Shares in both Fresenius and Fresenius Medical Care were up about 4% in early trade on Tuesday. Analysts said investors were relieved that a summer slowdown at Helios and a further negative impact from a U.S. dialysis treatment coordination programme known as ESCO did not materialize.
German healthcare group Fresenius beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business. The group said both Fresenius Medical Care, the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Fresenius confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros ($9.86 billion) in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.
Today we'll evaluate Fresenius SE & Co. KGaA (ETR:FRE) to determine whether it could have potential as an investment...
Today we'll take a closer look at Fresenius SE & Co. KGaA (ETR:FRE) from a dividend investor's perspective. Owning a...
German health care group Fresenius has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report. Sources had told Reuters in May that Fresenius had approached potential suitors about selling the unit and had hired Goldman Sachs for that purpose. "I confirm that the transfusion business will continue to be operated by Fresenius," a spokesman for the firm said in an email when asked about the report.
Today we'll evaluate Fresenius SE & Co. KGaA (FRA:FRE) to determine whether it could have potential as an investment...
‣ Record Revenue, Margins: Q2 set records on Product Revenue, Total Revenue, Direct Sales and Product Margin. CytoSorbents (CTSO) expects all three to be back online by year-end (one of which resumed ordering in Q2).
Increase in profitability and industry-beating performance can be essential considerations in a stock for some...